• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
Menu
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Rick Batycky joins Pulmatrix board of directors

Inhaled drug developer Pulmatrix has announced the appointment of Nocion Therapeutics CEO Rick Batycky to its board of directors. Batycky was a founder of Civitas Therapeutics, which developed Inbrija inhaled levodopa and which was acquired by Acorda in 2014. Prior to serving as Chief Scientific Officer at Civitas and then Chief Technology Officer at Acorda, Batycky had served as Chief Scientific Officer and Senior VP of R&D at Pulmatrix.

Pulmatrix CEO Ted Raad said, “Rick brings deep expertise in drug development to the board and we are thrilled to welcome him. His broad ranging experience in respiratory therapeutics, including Pulmatrix’s iSPERSE dry powder inhalation technology, will be invaluable as we consider opportunities to bring new therapeutics to market. We look forward to his strategic guidance as we strategically advance our iSPERSE platform.”

Batycky commented, “I believe that Pulmatrix’s iSPERSE platform technology has tremendous potential to improve the standard of care for patients suffering from serious pulmonary disease. I look forward to helping advance their critically important pipeline.”

Pulmatrix’s pipeline includes the Pulmazole (PUR1900) itraconazole DPI, which is in Phase 2 development for the treatment of allergic bronchopulmonary aspergillosis (ABPA). Earlier this year, Pulmatrix announced that it had partnered with Cip Tec on development of Pulmazole.

Read the Pulmatrix press release.

Share

published on November 4, 2019

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    © 2025 OINDPnews